Kieron Dunleavy invites you to join the virtual Lymphoma Hub Satellite Symposium on Nov 8, 2020

Interview with Kieron Dunleavy inviting you to the Lymphoma Hub virtual Satellite Symposium which will...

The prognostic value of PET scan in the treatment of DLBCL

A summary of two studies evaluating the outcomes of PET-guided treatment decisions in patients with limited-stage and advanced-stage DLBCL.

Lymphodepletion optimization for CAR T-cell therapy

A summary of the talk by Elizabeth Budde at the eighth annual meeting of the SOHO regarding the optimization of lymphodepletion protocols.

Liso-cel for relapsed/refractory large B-cell lymphoma: Results from TRANSCEND NHL 001

Results from the TRANSCEND NHL 001 study indicate that liso-cel could be a feasible treatment option for patients...

Tucidinostat received orphan drug designation in Japan for the treatment of R/R ATL

On September 28, 2020, tucidinostat (HBI-8000) received orphan drug designation by the Japanese Ministry of Health,...

FDA grants priority review for crizotinib in pediatric ALK-positive R/R ALCL

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application...

Tolinapant receives orphan drug designation from the FDA for the treatment of T-cell lymphoma

On August 31, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to...

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Subclassifying T-cell lymphomas (TCLs) is difficult due to the heterogeneity and...

Phase III CHRONOS-3 study evaluating copanlisib and rituximab combination meets primary endpoint

Phase III CHRONOS-3 study, evaluating copanlisib in combination with rituximab for relapsed iNHL, meets...

Liso-cel for relapsed/refractory large B-cell lymphoma: Results from TRANSCEND NHL 001

Results from the TRANSCEND NHL 001 study indicate that liso-cel could be a feasible treatment option for patients...

FDA grants fast track designation to novel combination CAR T-cell therapy, CLBR001 + SWI019, for B cell malignancies

On October 1, 2020, the U.S. Food and Drug Administration (FDA) granted fast track...

Update from SOHO 2020 on follicular lymphoma

Interview with Steering Committee member Nathan Fowler who provided an update on follicular lymphoma from the SOHO 2020 Meeting.